S

Shandong Boan Biotechnology Co Ltd
HKEX:6955

Watchlist Manager
Shandong Boan Biotechnology Co Ltd
HKEX:6955
Watchlist
Price: 8.86 HKD 0.91% Market Closed
Market Cap: 4.7B HKD
Have any thoughts about
Shandong Boan Biotechnology Co Ltd?
Write Note

Shandong Boan Biotechnology Co Ltd
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shandong Boan Biotechnology Co Ltd
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
S
Shandong Boan Biotechnology Co Ltd
HKEX:6955
Total Liabilities
ÂĄ1B
CAGR 3-Years
33%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Liabilities
ÂĄ16B
CAGR 3-Years
13%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Liabilities
ÂĄ7.9B
CAGR 3-Years
20%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Liabilities
ÂĄ3B
CAGR 3-Years
47%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Liabilities
ÂĄ23.3B
CAGR 3-Years
27%
CAGR 5-Years
32%
CAGR 10-Years
64%
Imeik Technology Development Co Ltd
SZSE:300896
Total Liabilities
ÂĄ504.4m
CAGR 3-Years
72%
CAGR 5-Years
51%
CAGR 10-Years
N/A
No Stocks Found

Shandong Boan Biotechnology Co Ltd
Glance View

Market Cap
4.5B HKD
Industry
Biotechnology

Shandong Boan Biotechnology Co., Ltd. operates as a biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization. The company is headquartered in Yantai, Shandong and currently employs 631 full-time employees. The company went IPO on 2022-12-30. The firm is engaged in the development, production and commercialisation of therapeutic antibodies, focusing on the therapeutic areas of oncology, metabolism, autoimmunology and ophthalmology. The firm has three main technology platforms: a fully human antibody transgenic mouse and phage display technology platform, a bispecific T-cell Engager technology platform, and an antibody drug coupling (ADC) technology platform. The firm operates mainly in the domestic Chinese market and overseas markets.

Intrinsic Value
12.74 HKD
Undervaluation 30%
Intrinsic Value
Price
S

See Also

What is Shandong Boan Biotechnology Co Ltd's Total Liabilities?
Total Liabilities
1B CNY

Based on the financial report for Dec 31, 2023, Shandong Boan Biotechnology Co Ltd's Total Liabilities amounts to 1B CNY.

What is Shandong Boan Biotechnology Co Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 3Y
33%

Over the last year, the Total Liabilities growth was 28%. The average annual Total Liabilities growth rates for Shandong Boan Biotechnology Co Ltd have been 33% over the past three years .

Back to Top